Matches in SemOpenAlex for { <https://semopenalex.org/work/W2125431864> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2125431864 endingPage "32" @default.
- W2125431864 startingPage "28" @default.
- W2125431864 abstract "Factors that influence the choice of anagrelide, hydroxyurea, or interferon-alfa (IFN-alpha) for treatment of essential thrombocythemia include efficacy, toxicity, and cost. Anagrelide has the US Food and Drug Administration's approval to be used for treating patients with thrombocythemia secondary to chronic myeloproliferative disorders. In contrast, the use of IFN-alpha and hydroxyurea are considered off-label. We performed an incremental cost-effectiveness analysis to compare anagrelide, hydroxyurea, and IFN-alpha for treating essential thrombocythemia, in terms of estimated impact on life expectancy. The case used for this analysis was of a 40-year-old man with essential thrombocythemia. Clinical assumptions were based on information obtained from nonrandomized clinical trials, and the economic assumptions were derived from information abstracted from observational studies. Lifelong treatment use of anagrelide versus hydroxyurea would cost approximately $72,000 per additional year of life gained, while the use of IFN-alpha was found to be both more costly and less effective than anagrelide. The results were very sensitive to the risk of leukemia caused by hydroxyurea, with an incremental cost-effectiveness of anagrelide compared with hydroxyurea of $156,969 per additional year of life gained if the lifetime leukemia risk drops from a baseline of .08 to.05. Given that many commonly used medical interventions cost in the range of $50,000 to $100,000 per year of life gained, and the generally poor outcome associated with treatment-related leukemia that can result from hydroxyurea, anagrelide could be considered a therapeutic alternative that is clinically effective at an acceptable cost." @default.
- W2125431864 created "2016-06-24" @default.
- W2125431864 creator A5033706484 @default.
- W2125431864 creator A5034676046 @default.
- W2125431864 creator A5037456539 @default.
- W2125431864 creator A5064139094 @default.
- W2125431864 date "2002-01-01" @default.
- W2125431864 modified "2023-10-18" @default.
- W2125431864 title "Cost-effectiveness considerations in the treatment of essential thrombocythemia" @default.
- W2125431864 cites W1446966563 @default.
- W2125431864 cites W1513929198 @default.
- W2125431864 cites W185908020 @default.
- W2125431864 cites W1965205173 @default.
- W2125431864 cites W2040917201 @default.
- W2125431864 cites W2055030955 @default.
- W2125431864 cites W2085319757 @default.
- W2125431864 cites W2085677832 @default.
- W2125431864 cites W2117054170 @default.
- W2125431864 cites W2149512712 @default.
- W2125431864 cites W2162617777 @default.
- W2125431864 cites W2444537720 @default.
- W2125431864 cites W2462238653 @default.
- W2125431864 cites W2465352900 @default.
- W2125431864 cites W46453237 @default.
- W2125431864 cites W2186220306 @default.
- W2125431864 doi "https://doi.org/10.1016/s0093-7754(02)70150-4" @default.
- W2125431864 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12096355" @default.
- W2125431864 hasPublicationYear "2002" @default.
- W2125431864 type Work @default.
- W2125431864 sameAs 2125431864 @default.
- W2125431864 citedByCount "2" @default.
- W2125431864 countsByYear W21254318642016 @default.
- W2125431864 crossrefType "journal-article" @default.
- W2125431864 hasAuthorship W2125431864A5033706484 @default.
- W2125431864 hasAuthorship W2125431864A5034676046 @default.
- W2125431864 hasAuthorship W2125431864A5037456539 @default.
- W2125431864 hasAuthorship W2125431864A5064139094 @default.
- W2125431864 hasConcept C126322002 @default.
- W2125431864 hasConcept C141071460 @default.
- W2125431864 hasConcept C177713679 @default.
- W2125431864 hasConcept C2778837598 @default.
- W2125431864 hasConcept C2781057849 @default.
- W2125431864 hasConcept C71924100 @default.
- W2125431864 hasConceptScore W2125431864C126322002 @default.
- W2125431864 hasConceptScore W2125431864C141071460 @default.
- W2125431864 hasConceptScore W2125431864C177713679 @default.
- W2125431864 hasConceptScore W2125431864C2778837598 @default.
- W2125431864 hasConceptScore W2125431864C2781057849 @default.
- W2125431864 hasConceptScore W2125431864C71924100 @default.
- W2125431864 hasIssue "3" @default.
- W2125431864 hasLocation W21254318641 @default.
- W2125431864 hasOpenAccess W2125431864 @default.
- W2125431864 hasPrimaryLocation W21254318641 @default.
- W2125431864 hasRelatedWork W2002120878 @default.
- W2125431864 hasRelatedWork W2003938723 @default.
- W2125431864 hasRelatedWork W2047967234 @default.
- W2125431864 hasRelatedWork W2118496982 @default.
- W2125431864 hasRelatedWork W2364998975 @default.
- W2125431864 hasRelatedWork W2439875401 @default.
- W2125431864 hasRelatedWork W2903749170 @default.
- W2125431864 hasRelatedWork W4238867864 @default.
- W2125431864 hasRelatedWork W2519357708 @default.
- W2125431864 hasRelatedWork W2525756941 @default.
- W2125431864 hasVolume "29" @default.
- W2125431864 isParatext "false" @default.
- W2125431864 isRetracted "false" @default.
- W2125431864 magId "2125431864" @default.
- W2125431864 workType "article" @default.